NCT01115387Active, not recruiting

GARM II: A Study on the Genetics of Age-related Maculopathy

Genetics of Age Related Maculopathy

Source: ClinicalTrials.gov · Last updated 7 Nov 2023

Brief summary (registry, in English)

The original study (GARM I) has been conducted for more than 18 years at the University of Pittsburgh Medical Center (UPMC). GARM II is a nationwide research study about age-related macular degeneration in the next generation of adults (49 to 65 years old). The purpose of this study is to identify the hereditary and exposure risk factors that lead to the development of ARM (Age related maculopathy). Participants will communicate with the research staff through a protected and confidential website and use this website to complete a number of questionnaires during the course of the study (see below). For genetic analyses, the participants will mail in easily self-collected saliva samples in special containers. Eye photographs and eye health records are sent to the research center from local sources through the Internet. Individuals are not expected to come to UCLA in order to participate. https://jseiclinres.jsei.ucla.edu/garm/ Participants will be expected to answer questionnaires or surveys about medical history, ocular history and visual symptoms, family history, smoking, dietary supplements and light exposure.

Status (registry): Active, not recruiting
Study type: Observational
Enrollment: 603 (actual)
First submitted: 26 Apr 2010
Start date: 6 Oct 2011
Primary completion date: 29 Feb 2016
Lead sponsor: University of California, Los Angeles
Diseases: Macular degeneration
NCT number: NCT01115387

What you commit to

Study type: Observational
Participants enrolled: 603
From 6 Oct 2011 to the primary completion date, 29 Feb 2016
2 sites in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

Inability to give informed consent. Adaptations will be provided to allow those who are unable to read because of vision loss to participate in the informed consent process.(Proxy)
For the at risk individuals and their spouses/partners, they will be excluded if they do not have access and the ability to use a computer that is connected to the Internet.

Who the study is looking for

Individuals should have an email account and access to the Internet in order to use the website for this study. Individuals who are unfamiliar or physically challenged with using computers may have another person assist them with reviewing messages, questions and entering information and making inquiries.
ARM at-risk individuals between the ages of 49 to 65 years old who have at least one parent either deceased or alive with diagnosis of macular degeneration. This group includes the "third generation children" of our original GARM study.
Individuals between the ages of 49 to 65 years old who are either a spouse or partner of an ARM at-risk adult (those individuals described above with a parent diagnosed with ARM).
Individuals who have vision loss from ARM and a known family history of ARM (at least a brother, sister, or a parent). These individuals should have at least one at-risk child between the ages of 49 to 65 years old who is willing to participate in this study.

Age in the registry: 49 years to - · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Jules Stein Eye Institute, Dept. of Ophthalmology David Geffen School of Medicine at UCLA Coordinator of this site? Confirm its status	Los Angeles	United States	Unknown status
University of Pittsburgh Coordinator of this site? Confirm its status	Pittsburgh	United States	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.